Latest Obesity Updates: Zealand’s Obesity Strategy, $2.2B Novo Deal, China’s Mazdutide Challenge and more
In this week’s Obesity Updates, we’re spotlighting the biggest moves in obesity care — from executive leadership shifts and billion-dollar drug deals to China’s bold push to rival global brands.
Key updates include:
👨⚕️ Zealand Pharma names Steven Johnson as CDO to lead obesity R&D
💊 Novo Nordisk inks $2.2B obesity drug deal with Septerna
🐉 China’s Innovent pushes mazdutide into Phase 3 to rival semaglutide
🤝 Skye and Arecor team up on nimacimab formulation
🩺 EndoZip shows safety promise as a non-surgical obesity option
Discover how these global players are reshaping the future of obesity treatment through science, strategy, and scale.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #GLP1Therapies #ObesityTreatment #BiotechNews #Semaglutide #WeightLossScience #PharmaInnovation #LucidQuest #ClinicalTrials #HealthcareUpdates